Danazol
- Generic Name
- Danazol
- Brand Names
- Cyclomen
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27NO2
- CAS Number
- 17230-88-5
- Unique Ingredient Identifier
- N29QWW3BUO
- Background
A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.
- Indication
For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females.
- Associated Conditions
- Endometriosis, Fibrocystic Disease of Breast, Hereditary Angioedema (HAE), Refractory immune thrombocytopenia
Endometriosis Clinical Trial Pipeline Shows Promise with 20+ Therapies in Development
• The endometriosis clinical trial landscape is robust, featuring over 15 companies developing more than 20 potential therapies.
• Recent clinical trial activity includes positive Phase II results for Hope Medicine's HMI-115 and TiumBio's Merigolix, alongside Lisata Therapeutics' preclinical research.
• Key companies like Kissei Pharmaceutical, Mithra Pharmaceuticals, and Organon are advancing novel treatments, including Linzagolix and Estelle, to address unmet needs.
• These emerging therapies aim to improve pain management and overall outcomes for the estimated 190 million women affected by endometriosis worldwide.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath